Association of beta-2 adrenergic agonist and corticosteroid injection in the treatment of lipomas

作者：Redman L M; Moro C; Dobak J; Yu Y; Guillot T S; Greenway F L^*

来源：Diabetes, Obesity and Metabolism, 2011, 13(6): 517-522.

DOI：10.1111/j.1463-1326.2011.01374.x

• adipose tissue
• cellular pharmacology
• clinical trial
• drug mechanism
• fat
• obesity therapy

Methods: The first experiment evaluated in vitro lipolysis induced by isoproterenol 10-6 M alone and across a range of prednisolone concentrations to determine the optimal dose to maximize lipolysis. The second experiment evaluated lipolysis in a lipoma and subcutaneous fat by in vivo microdialysis in five subjects to isoproterenol 10-6 M with and without prednisolone 10-6 M. These five subjects and five additional subjects had a lipoma treated five times a week for 4 weeks in a 4-cm grid with 0.2 ml injections of 10-6 M isoproterenol and 10-6 M prednisolone. Lipoma size was followed monthly for 1 year or until surgical removal.
Results: Prednisolone increased in vitro lipolysis to isoproterenol and 10-6 M was the optimal concentration of both drugs. Lipomas responded with less lipolysis to isoproterenol than subcutaneous fat during microdialysis, and prednisolone treatment increased lipolysis in both lipomas and subcutaneous fat. Injection treatment of the lipomas decreased their volume 50%. All but one lipoma grew after treatment. Eight of the 10 subjects elected for surgical treatment, and the histology of the lipomas was normal fat tissue.
Conclusions: Prednisolone and isoproterenol in combination increased lipolysis, and injections of the combination into lipomas decreased their volume 50% over 4 weeks. Eight of the 10 subjects elected for surgical removal.

• 出版日期2011-6